Yukihiro Toi

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 4

Top Topics

Advanced Non Small Cell Lung Cancer

Randomized Controlled Trial

Epidermal Growth Factor Receptor

Left Ventricular

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L). Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Tsuyoshi Isawa, Yukihiro Toi, Shunichi Sugawara, Masataka Taguri, Shigeru Toyoda
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. The oncologist 27 (5) (2022)
Yukihiro Toi, Shunichi Sugawara, Yosuke Kawashima, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Kyoji Tsurumi, Kana Suzuki, Hisashi Shimizu, Jun Sugisaka, Hirotaka Ono, Yutaka Domeki, Keisuke Terayama, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Yoshihiro Honda
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. The oncologist 23 (11) (2018)